Advertisement

 

 

EUS-guided Biliary Drainage for Malignant Perihilar Biliary Strictures after Further Transpapillary Intervention has been Judged to be Impossible or Ineffective.

EUS-guided Biliary Drainage for Malignant Perihilar Biliary Strictures after Further Transpapillary Intervention has been Judged to be Impossible or Ineffective.
Author Information (click to view)

Kanno Y, Ito K, Koshita S, Ogawa T, Masu K, Kusunose H, Sakai T, Masaki Y, Murabayashi T, Hasegawa S, Kozakai F, Horaguchi J, Matsuo H, Noda Y,


Kanno Y, Ito K, Koshita S, Ogawa T, Masu K, Kusunose H, Sakai T, Masaki Y, Murabayashi T, Hasegawa S, Kozakai F, Horaguchi J, Matsuo H, Noda Y, (click to view)

Kanno Y, Ito K, Koshita S, Ogawa T, Masu K, Kusunose H, Sakai T, Masaki Y, Murabayashi T, Hasegawa S, Kozakai F, Horaguchi J, Matsuo H, Noda Y,

Advertisement

Internal medicine (Tokyo, Japan) 2017 10 11() doi 10.2169/internalmedicine.9001-17
Abstract

Objective Patients with perihilar malignancy often develop recurrence of infectious cholangitis, which makes further transpapillary intervention extremely difficult. As EUS-guided biliary drainage (EUS-BD) of an intrahepatic bile duct is a possible option for additional intervention, the aim of this study was to estimate the feasibility of such intervention. Methods and Patients Patients who had undergone EUS-BD after further transpapillary intervention was deemed impossible or ineffective were investigated in this study. Those who had not received previous interventions via the papilla were excluded. Procedure-related adverse events, clinical efficacy, and time to recurrence of jaundice or infectious cholangitis (TTR) were evaluated. Results Seven patients were eligible for the study between 2007 and 2016 (7 men; mean age, 77 years; 4 with perihilar cholangiocarcinoma and 3 with intrahepatic cholangiocarcinoma). No procedure-related adverse events were observed. EUS-BD was clinically effective and enabled hospital discharge in 4 patients (57%). The TTR in these 4 clinically effective patients was 43, 105, 118, and 147 days after the procedure (median, 112 days). Conclusion EUS-BD was found to be safe and often effective in patients in whom additional transpapillary intervention had become difficult, although its efficacy was limited to a short period.

Submit a Comment

Your email address will not be published. Required fields are marked *

seven + 4 =

[ HIDE/SHOW ]